Danaher Corp
Chiusa
SettoreSettore sanitario
179.88 -0.38
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
179.17
Massimo
180.7
Entrata | -168M 1B |
|---|---|
Vendite | -887M 6B |
P/E Media del settore | 35.568 49.052 |
EPS | 2.06 |
Rendimento da dividendi | 0.74 |
Margine di Profitto | 17.291 |
Dipendenti | 58,000 |
EBITDA | -514M 1.5B |
Raccomandazioni | Fortemente da comprare |
|---|---|
Previsioni per 12 mesi | +27.04% upside |
Rendimento da dividendi Media del settore | 0.74% 2.36% |
|---|---|
Utili prossimi | 21 lug 2026 |
Prossima data del Dividendo | 31 lug 2026 |
Prossima data del' Ex Dividendo | 26 giu 2026 |
Capitalizzazione di Mercato | -8.5B 130B |
|---|---|
Apertura precedente | 180.26 |
Chiusura precedente | 179.88 |
Notizie sul Sentiment di mercato
By Acuity
32%
68%
80 / 342 Classifica in Healthcare
Danaher Corp Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Chi Siamo Danaher Corp
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.